ePRO-supported monitoring and chemotherapy dose intensity in early-stage breast cancer: a retrospective study dataset
Description
This de-identified dataset supports a retrospective analysis of ePRO use and chemotherapy intensity in early-stage breast cancer.
Files
Steps to reproduce
This dataset was used in a retrospective observational study to assess the association between the use of electronic patient-reported outcomes (ePRO) and chemotherapy dose intensity (ARDI) and adverse events in patients with early-stage breast cancer. Statistical analyses were conducted using JMP® Pro 17.0.0 (SAS Institute Inc.). The ARDI for each cytotoxic agent was calculated as: (Actual total dose / Actual duration in weeks) ÷ (Standard total dose / Standard duration in weeks) × 100 (%) ARDI values were then averaged across all cytotoxic agents in each regimen to derive ARDI per patient. Unresolved Grade ≥2 non-hematologic adverse events were defined as events persisting at the start of the next chemotherapy cycle, based on ePRO records and pharmacist documentation. Data were anonymized prior to analysis. Refer to the README file and Data Dictionary for variable definitions and coding details. Reproduction of results requires standard statistical software and application of the same definitions and thresholds (e.g., ARDI ≥85%).